CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy

Experimental Dermatology

Volumn 19, Issue 3, 2010, Pages 246-251

  Kwon, Yeon Sook ^a   Oh, Sang Ho ^a   Wu, Wen Hao ^a   Bae, Byung Gi ^a   Lee, Hee Jung ^b   Lee, Min Geol ^a   Lee, Kwang Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Police Hospital   (South Korea)

Author keywords

Atopic dermatitis; CCL17; CCL18; CCL22; Immunotherapy with house dust mites

Indexed keywords

ALAVAC; ANTIHISTAMINIC AGENT; BETA CHEMOKINE; CHEMOKINE CCL18; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; MACROPHAGE DERIVED CHEMOKINE; STEROID; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; DRUG DOSE INCREASE; ECZEMA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; PRICK TEST; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BIOLOGICAL MARKERS; CHEMOKINE CCL17; CHEMOKINE CCL22; CHEMOKINES, CC; CHILD; DERMATITIS, ATOPIC; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; YOUNG ADULT;

EID: 77149170355     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00971.x     Document Type: Article

References (23)

1. Hanifin J M. Atopic dermatitis. J Allergy Clin Immunol 1984, 73:211-226.
2. Bieber T. Atopic dermatitis. N Engl J Med 2008, 358:1483-1494.
3. Leung D Y. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000, 105:860-876.
4. Beltrani V S. The role of house dust mites and other aeroallergens in atopic dermatitis. Clin Dermatol 2003, 21:177-182.
5. Des Roches A, Paradis L, Menardo J L, Bouges S, Daurés J P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450-453.
6. Larche M, Akdis C A, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761-771.
7. Akdis M, Akdis C A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 119:780-791.
8. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006, 118:1292-1298.
9. Werfel T, Breuer K, Ruéff F. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multicentre, randomized, dose-response study. Allergy 2006, 61:202-205.
10. Bussmann C, Maintz L, Hart J. Clinical improvement and immunological changes of atopic dermatitis patients undergoing subcutaneous allergen-specific immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007, 37:1277-1285.
11. Czarnecka-Operacz M, Silny W. Immunological parameters in the sera of patients with atopic dermatitis and airborne allergy treated with allergy vaccines. Acta Dermatovenerol Croat 2006, 14:8-20.
12. Choi Y J, Choi H J, Cho H J. Effect of hyposensitization to Dermatophagoides farinae in patients with atopic dermatitis. Korean J Invest Dermatol 2001, 8:123-128.
13. Kakinuma T, Nakamura K, Wakugawa M. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol 2002, 127:270-273.
14. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005, 60:685-688.
15. Pivarcsi A, Gombert M, Dieu-Nosjean M C. CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol 2004, 173:5810-5817.
16. Hanifin J M, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980, 92(Suppl.):44-47.
17. Leung D Y, Boguniewicz M, Howell M D, Nomura I, Hamid Q A. New insights into atopic dermatitis. J Clin Invest 2004, 113:651-657.
18. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007, 7:542-546.
19. Silny W, Czarnecka-Operacz M. Specific immune therapy in the treatment of patients with atopic dermatitis. Allergologie 2006, 29:171-183.
20. Wachholz P A, Durham S R. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004, 4:313-318.
21. Gunther C, Bello-Fernandez C, Kopp T. CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 2005, 174:1723-1728.
22. Homey B, Meller S, Savinko T, Alenius H, Lauerma A. Modulation of chemokines by staphylococcal superantigen in atopic dermatitis. Chem Immunol Allergy 2007, 93:181-194.
23. Park C O, Lee H J, Lee J H. Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients. Exp Dermatol 2008, 17:24-29.